Carfilzomib, Daratumumab, and Dexamethasone (KdD) Vs Carfilzomib and Dexamethasone (Kd) for Relapsed/Refractory Multiple Myeloma (RRMM) in the Phase 3 Candor Study: Subgroup Analysis According to Renal Functioning

被引：0

作者：

Dimopoulos, Meletios Athanasios ^{[1
]}

Landgren, Ola ^{[2
]}

Siegel, David S. ^{[3
]}

Grosicki, Sebastian ^{[4
]}

Oriol, Albert ^{[5
,6
]}

Najdi, Rani ^{[7
]}

Li, Chuang ^{[7
]}

Mezzi, Khalid ^{[7
]}

Shu, Natalie ^{[8
]}

Quach, Hang ^{[9
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece

[2] Univ Miami, Myeloma Div, Sylvester Comprehens Canc Ctr, Miami, FL USA

[3] Hackensack Univ, Med Ctr, Multiple Myeloma Div, Hackensack, NJ USA

[4] Med Univ Silesia, Fac Hlth Sci, Dept Hematol & Canc Prevent, Katowice, Poland

[5] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain

[6] Hosp Badalona Germans Trias & Pujol, Josep Carreras Inst, Badalona, Spain

[7] Amgen Inc, Thousand Oaks, CA USA

[8] Paraxel, Chengdu, Peoples R China

[9] St Vincents Hosp Melbourne, East Melbourne, Australia

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-190726

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Carfilzomib, Dexamethasone, and Daratumumab (KdD) Versus Carfilzomib and Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma (RRMM): Subgroup Analysis of the Phase 3 CANDOR Study by Number of Prior Lines of Therapy (pLOTs) and Prior Therapies
Quach, Hang
Nooka, Ajay
Samoylova, Olga
Venner, Christopher
Kim, Kihyun
Facon, Thierry
Spencer, Andrew
Usmani, Saad
Grosicki, Sebastian
Suzuki, Kenshi
Delimpasi, Sosana
Weisel, Katja
Obreja, Mihaela
Zahlten-Kumeli, Anita
Mateos, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S294 - S294
[2] Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse
Weisel, Katja
Geils, George F.
Karlin, Lionel
Mollee, Peter
Chung, Tae-Hoon
Min, Chang-Ki
Sunami, Kazutaka
Goldrick, Amanda
Fang, Belle
Fowler, Jessica
Mateos, Maria-Victoria
BLOOD, 2020, 136
[3] Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study
Dimopoulos, Meletios A.
Quach, Hang
Mateos, Maria-Victoria
Landgren, Ola
Leleu, Xavier
Siegel, David S.
Weisel, Katja
Gavriatopoulou, Maria
Oriol, Albert
Rabin, Neil K.
Nooka, Ajay
Qi, Ming
Ding, Bifeng
Zahlten-Kumeli, Anita
Usmani, Saad Z.
BLOOD, 2020, 136
[4] Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
Usmani, Saad Z.
Quach, Hang
Mateos, Maria-Victoria
Landgren, Ola
Leleu, Xavier
Siegel, David
Weisel, Katja
Shu, Xiaomei
Li, Chuang
Dimopoulos, Meletios
BLOOD ADVANCES, 2023, 7 (14) : 3739 - 3748
[5] Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial
Kenshi Suzuki
Chang-Ki Min
Kihyun Kim
Je-Jung Lee
Hirohiko Shibayama
Po-Shen Ko
Shang-Yi Huang
Sin-Syue Li
Bifeng Ding
Monica Khurana
Shinsuke Iida
International Journal of Hematology, 2021, 114 : 653 - 663
[6] Health related quality of life (HRQoL) outcomes from the phase III CANDOR study comparing carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients (Pts) with relapsed or refractory multiple myeloma.
Siegel, David Samuel DiCapua
Weisel, Katja
Zahlten-Kumeli, Anita
Medhekar, Rohan
Sapra, Sandhya
Ding, Bifeng
Leleu, Xavier
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[7] Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial
Suzuki, Kenshi
Min, Chang-Ki
Kim, Kihyun
Lee, Je-Jung
Shibayama, Hirohiko
Ko, Po-Shen
Huang, Shang-Yi
Li, Sin-Syue
Ding, Bifeng
Khurana, Monica
Iida, Shinsuke
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 114 (06) : 653 - 663
[8] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Dimopoulos, Meletios
Quach, Hang
Mateos, Maria-Victoria
Landgren, Ola
Leleu, Xavier
Siegel, David
Weisel, Katja
Yang, Hui
Klippel, Zandra
Zahlten-Kumeli, Anita
Usmani, Saad Z.
LANCET, 2020, 396 (10245): : 186 - 197
[9] Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy
Quach, Hang
Nooka, Ajay
Samoylova, Olga
Venner, Christopher P.
Kim, Kihyun
Facon, Thierry
Spencer, Andrew
Usmani, Saad Z.
Grosicki, Sebastian
Suzuki, Kenshi
Delimpasi, Sosana
Weisel, Katja
Obreja, Mihaela
Zahlten-Kumeli, Anita
Mateos, Maria-Victoria
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (04) : 784 - 788
[10] Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)
Chari, Ajai
Lonial, Sagar
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Blade, Joan
Benboubker, Lotfi
Oriol, Albert
Otero, Paula Rodriguez
Pineiro, Luis
Jakubowiak, Andrzej
Olyslager, Yunsi
Wang, Jianping
Nnane, Ivo
Ukropec, Jon
Shreeve, Martin
Qi, Ming
Moreau, Philippe
BLOOD, 2019, 134

← 1 2 3 4 5 →